Immunotherapy boost may improve outcomes in returning throat cancer

NCT ID NCT03907826

First seen May 10, 2026 · Last updated May 13, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding an immunotherapy drug (PD-1 antibody) to standard chemoradiotherapy helps people with recurrent nasopharyngeal carcinoma live longer. About 212 participants whose cancer has returned after prior treatment and cannot be surgically removed will be randomly assigned to receive either the combination or chemoradiotherapy alone. The study measures survival, tumor shrinkage, side effects, and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    NOT_YET_RECRUITING

    Shanghai, China

    Contact

  • Fujian Province Cancer Hospital

    NOT_YET_RECRUITING

    Fuzhou, China

    Contact

  • Guizhou Cancer Hospital

    RECRUITING

    Guiyang, China

    Contact

  • Jiangxi Cancer Hospital

    NOT_YET_RECRUITING

    Nanchang, China

    Contact

  • Peking University Third Hospital

    NOT_YET_RECRUITING

    Beijing, China

    Contact

  • Sichuan Cancer Hospital

    NOT_YET_RECRUITING

    Chengdu, China

    Contact

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Guangxi Medical University

    RECRUITING

    Nanning, China

    Contact

  • The First Affiliated Hospital of Xiamen University

    NOT_YET_RECRUITING

    Xiamen, China

    Contact

  • Xijing Hospital

    RECRUITING

    Xi'an, China

    Contact

  • Zhejiang Cancer Hospital

    NOT_YET_RECRUITING

    Hangzhou, China

    Contact

  • Zhongnan Hospital of Wuhan University

    RECRUITING

    Wuhan, China

    Contact

Conditions

Explore the condition pages connected to this study.